Insider Transactions in Q4 2022 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,316
-4.93%
|
$1,015,800
$50.97 P/Share
|
|
Dec 29
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,816
+3.57%
|
$218,848
$28.35 P/Share
|
|
Dec 28
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,700
-0.83%
|
$85,000
$50.0 P/Share
|
|
Dec 28
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+0.82%
|
$47,600
$28.35 P/Share
|
|
Dec 28
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
999
-4.06%
|
$48,951
$49.76 P/Share
|
|
Dec 28
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
999
+3.9%
|
$6,993
$7.01 P/Share
|
|
Dec 27
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,001
-44.58%
|
$931,049
$49.77 P/Share
|
|
Dec 27
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,001
+30.83%
|
$133,007
$7.01 P/Share
|
|
Dec 27
2022
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-6.41%
|
$612,500
$49.57 P/Share
|
|
Dec 27
2022
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+3.05%
|
$37,500
$3.49 P/Share
|
|
Dec 16
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+2.24%
|
$0
$0.62 P/Share
|
|
Dec 12
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.75%
|
$215,000
$43.48 P/Share
|
|
Dec 09
2022
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+9.52%
|
-
|
|
Dec 09
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+8.64%
|
-
|
|
Dec 09
2022
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
52,351
+12.62%
|
-
|
|
Dec 09
2022
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+17.38%
|
-
|
|
Dec 09
2022
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+44.83%
|
-
|
|
Dec 01
2022
|
Skorpios Trust |
SELL
Open market or private sale
|
Indirect |
1,636,000
-33.33%
|
$70,348,000
$43.5 P/Share
|
|
Dec 01
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.12%
|
$460,000
$46.07 P/Share
|
|
Dec 01
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.03%
|
$0
$0.62 P/Share
|
|
Nov 30
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
12,030
-3.83%
|
$565,410
$47.02 P/Share
|
|
Nov 30
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
11,101
-3.84%
|
$521,747
$47.02 P/Share
|
|
Nov 16
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,947
-1.05%
|
$177,615
$45.75 P/Share
|
|
Nov 15
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,138
-1.64%
|
$141,210
$45.04 P/Share
|
|
Nov 10
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.25%
|
$195,000
$39.68 P/Share
|
|
Nov 01
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.04%
|
$430,000
$43.21 P/Share
|
|
Nov 01
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.03%
|
$0
$0.62 P/Share
|
|
Oct 28
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
22,965
-6.31%
|
$918,600
$40.7 P/Share
|
|
Oct 28
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
21,138
-6.3%
|
$845,520
$40.7 P/Share
|
|
Oct 27
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
72,172
-10.27%
|
$3,031,224
$42.13 P/Share
|
|
Oct 27
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
66,426
-10.27%
|
$2,789,892
$42.13 P/Share
|
|
Oct 26
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
71,583
-7.86%
|
$3,078,069
$43.98 P/Share
|
|
Oct 26
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
65,885
-7.86%
|
$2,833,055
$43.98 P/Share
|
|
Oct 26
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,762
-2.43%
|
$214,290
$45.03 P/Share
|
|
Oct 25
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
4,906
-1.48%
|
$215,864
$44.92 P/Share
|
|
Oct 25
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
4,515
-1.48%
|
$198,660
$44.92 P/Share
|
|
Oct 25
2022
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-7.11%
|
$550,000
$44.72 P/Share
|
|
Oct 25
2022
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.64%
|
$75,000
$6.36 P/Share
|
|
Oct 25
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,653
-5.16%
|
$479,385
$45.09 P/Share
|
|
Oct 25
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.36%
|
$170,000
$17.36 P/Share
|
|
Oct 13
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-81.87%
|
$780,000
$39.82 P/Share
|
|
Oct 13
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+45.02%
|
$140,000
$7.01 P/Share
|
|
Oct 10
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.09%
|
$185,000
$37.99 P/Share
|
|
Oct 06
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
22,500
-10.77%
|
$877,500
$39.29 P/Share
|
|
Oct 06
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.57%
|
$210,000
$21.09 P/Share
|
|
Oct 03
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.05%
|
$330,000
$33.59 P/Share
|
|
Oct 03
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.03%
|
$0
$0.62 P/Share
|